The clinical trial aimed to evaluate the efficacy of the FreeStyle Libre 2 system in promoting weight reduction among individuals with Type 2 Diabetes compared to the current standard of care. The trial was terminated due to slow enrollment and the study being deemed no longer required. This outcome suggests potential challenges in market adoption or interest in the comparative efficacy of glucose monitoring systems for weight management. Abbott Diabetes Care may need to reassess its strategy regarding the FreeStyle Libre 2, particularly in the context of competitive offerings in diabetes management and weight loss solutions. The termination of the trial may also impact investor confidence and future funding opportunities for related research.